Brief Summary

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas \[RESOS\] / French expert network dedicated to the pathology of sarcomas \[RREPS\]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas \[NETSARC\]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples. Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes. With the financial support of the French National Cancer Institute \[Institut National du cancer \[INCa\]).

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

150,000

participants targeted

Target at P75+ for all trials

Timeline

118mo left

Started Jan 2010

Longer than P75 for all trials

Geographic Reach

1 country

3 active sites

Status

recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

26 years study duration

Study Progress63%

Jan 2010Dec 2035

Study Start

First participant enrolled

January 1, 2010

Completed

9.4 years until next milestone

First Submitted

Initial submission to the registry

June 5, 2019

Completed

1 day until next milestone

First Posted

Study publicly available on registry

June 6, 2019

Completed

11.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2030

Expected

5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2035

Last Updated

September 4, 2025

Status Verified

August 1, 2025

Enrollment Period

21 years

First QC Date

June 5, 2019

Last Update Submit

August 28, 2025

Conditions

Sarcoma

Keywords

patterns of careaccess to caresurvivalexperts' network

Outcome Measures

Primary Outcomes (4)

Time to next treatment (TNT)
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
2 years
Time to next treatment (TNT)
Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.
5 years
Overall survival (OS)
Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.
2 years
Overall survival (OS)
Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.
5 years

Study Arms (1)

Patients with sarcoma

Patients with a sarcoma diagnosed in a French Comprehensive cancer Center

Drug: ChemotherapyDrug: Immunotherapeutic AgentDrug: target treatmentProcedure: SurgeryRadiation: Radiotherapy